Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Nov 2023
Historique:
received: 01 08 2023
revised: 14 09 2023
accepted: 04 10 2023
medline: 27 11 2023
pubmed: 22 10 2023
entrez: 21 10 2023
Statut: ppublish

Résumé

Ataxin-3 (Atxn3) is a deubiquitinase with a polyglutamine (polyQ) repeat tract whose abnormal expansion causes the neurodegenerative disease, Spinocerebellar Ataxia Type 3 (SCA3; also known as Machado-Joseph Disease). The ubiquitin chain cleavage properties of Atxn3 are enhanced when the enzyme is itself ubiquitinated at lysine (K) at position 117: in vitro, K117-ubiqutinated Atxn3 cleaves poly-ubiquitin markedly more rapidly compared to its unmodified counterpart. How polyQ expansion causes SCA3 remains unclear. To gather insights into the biology of disease of SCA3, here we posited the question: is K117 important for toxicity caused by pathogenic Atxn3? To answer this question, we generated transgenic Drosophila lines that express full-length, human, pathogenic Atxn3 with 80 polyQ with an intact or mutated K117. We found that mutating K117 mildly enhances the toxicity and aggregation of pathogenic Atxn3. An additional transgenic line that expresses Atxn3 without any K residues confirms increased aggregation of pathogenic Atxn3 whose ubiquitination is perturbed. These findings suggest that Atxn3 ubiquitination is a regulatory step of SCA3, in part by modulating its aggregation.

Identifiants

pubmed: 37865002
pii: S0022-510X(23)00289-7
doi: 10.1016/j.jns.2023.120828
pii:
doi:

Substances chimiques

Ataxin-3 EC 3.4.19.12
Lysine K3Z4F929H6
Ubiquitin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120828

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they do not have any conflicts of interest to disclose.

Auteurs

Jessica R Blount (JR)

Department of Pharmacology, Wayne State University, United States of America.

Nikhil C Patel (NC)

Department of Pharmacology, Wayne State University, United States of America.

Kozeta Libohova (K)

Department of Pharmacology, Wayne State University, United States of America.

Autumn L Harris (AL)

Department of Pharmacology, Wayne State University, United States of America; Maximizing Access to Research Careers, Wayne State University, United States of America.

Wei-Ling Tsou (WL)

Department of Pharmacology, Wayne State University, United States of America.

Alyson Sujkowski (A)

Department of Pharmacology, Wayne State University, United States of America. Electronic address: asujkows@med.wayne.edu.

Sokol V Todi (SV)

Department of Pharmacology, Wayne State University, United States of America; Maximizing Access to Research Careers, Wayne State University, United States of America; Department of Neurology, Wayne State University, United States of America. Electronic address: stodi@wayne.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH